CYCLACEL PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.69 USD | +2.42% |
|
-15.50% | -36.70% |
Presenter SpeechTara Sobierajski (Attendees)Good morning, and welcome to the Cyclacel Pharmace...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Calendar
2024-06-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.69
USD
Average target price
11
USD
Spread / Average Target
+550.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.70% | 2.47M | |
| +18.15% | 124B | |
| +18.02% | 112B | |
| +5.07% | 22.94B | |
| -12.75% | 22.22B | |
| -9.86% | 17.02B | |
| -14.97% | 16.88B | |
| -39.94% | 16.87B | |
| +2.80% | 13.63B | |
| +27.39% | 11.61B |
- Stock Market
- Equities
- CYCC Stock
- News Cyclacel Pharmaceuticals, Inc.
- Transcript : Cyclacel Pharmaceuticals, Inc. - Special Call
